Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study testing the safety and tolerability of BGB-21447 monotherapy in
participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study aims to determine the
maximum tolerated dose, recommended Phase 2 dose, and pharmacokinetic profile of the drug.
Additionally, preliminary antitumor activity will be characterized. The study includes three
cohorts and will also evaluate the safety and tolerability of a ramp-up dosing schedule.